Theralase Technologies Inc. V.TLT

Canadian & US Bladder Cancer

[99942Apophis]

Its estimated 12,000 Canadian and 84,000 US people will get Bladder Cancer this year. If Theralase were to get break through designation approval for 2022 then perhaps in 2023 they might get some of those patients. Let's say 10% of those patients using TLT's treatment, so we would be looking at 9,600 patients, lets round it off to 10,000 at a cost of say 50,000 (low ballpark figure) works out to gross total of 500,000,000 in their first year in only North America. Yes I have not taken into account cost to the company to treat these patients so without any knowledge of what that could be I'll just use a fictitious number of 100,000,000 leaving a net profit of 400,000,000.

Now comes a very very rough peek at the share price by divide profit by number of shares, so in 2023 we could be looking at say a few more shares than our current total so let's use 250M equals $1.60 per share ok! So what ratio will be awarded to this stock probably not the average ratio of low 20's (would be $32.00) more likely stocks that demonstrate they have something superior than competition could be awarded a ridiculous ratio 50?, 75?, 100? 

All just guesswork on my part, have a good day!

[skys1]

Apophis - IMO, earnings per/share won't come into play as someone will take out TLT after they achieve BTD, even before they start treating patients themsleves. Their ACT would be far too valuable for Big Pharma to just sit there and watch TLT operate while stealing Big Pharma's very profitable cancer treatment business. Big Pharma will make a move before they allow that to happen. If in

[99942Apophis]

Anything is possible skys1, I had a little time to draw up very rough numbers on what we could be looking at should initial commercialize occur here in only Canada and United States. If Theralase rejects bids by large Pharmas as inadequate then they could go into commercialization with already established partners and with guidance from Li Ka Shing. I'm also confident with good numbers out of

[CancerSlayer]

  Agree Apophis..."continuing independence" is the best option imo.  Bids would be pitifully low at the BTD stage, & even if we were to get approval for one indication, our multi-indication potential would still likely be way undervalued.  Access to private/public financing should come more easily with a BTD/approval in hand, & I would hope we have at least one

[socksnblonds642]

Maybe BioCanRx could be an option. They seem to be focusing on immunotheraoies but I do see that Bladder Cancer Canada is a partner as well as big pharma. People have already mentioned here that maybe our own government will show interest.    https://biocanrx.com/  

[StevenBirch]

I agree with you Skys and I think any buyout would not come after just one indication - depending on how close they are to starting Phase I trials for GBM and NSCLC. Getting BTD would be more than enough to make the wait worthwhile however. And how would getting that BTD for bladder affect how long it takes for someone to make a bid for everything? That's how bidding wars are started.

[skys1]

I agree Steven, and BTD is probably the factor that could start that process off. Usually a bidding war doesn't ensue until after the second offer is made, if there is one.

[patience69]

99942   I love your guess work. Keep ideas like that coming. To me the curious point is once we have BTD the thought is that we are destined for that kind of success. So when does the thought of those numbers start to show up in our share price??

[Oilminerdeluxe]

That BTD. What is required by TLT in order to achieve it? How stellar must the results be realistically?